-

Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer.

To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participants via email.

Conference Call Registration Link (Please register to obtain the dial-in number):
https://registrations.events/direct/Q4I4072834

A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Contacts

Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com

Media Contact: Evan Lamb
(949) 396-3376
elamb@masimo.com

Masimo

NASDAQ:MASI

Release Versions

Contacts

Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com

Media Contact: Evan Lamb
(949) 396-3376
elamb@masimo.com

More News From Masimo

Masimo Reports Third Quarter 2025 Results

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis; Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basis(2); GAAP net income per diluted share of $0.99; and Non-GAAP net income per diluted share(2) of $1.32, representing 38%...

Masimo to Report Third Quarter 2025 Financial Results after Market Close on Tuesday, November 4

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2025 financial results for the period ended September 27, 2025, after the market closes on Tuesday, November 4, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering,...

In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones

IRVINE, Calif.--(BUSINESS WIRE)--A feasibility study for a large real-world trial found Masimo SET® pulse oximetry performed accurately on critically ill patients of all skin tones....
Back to Newsroom